Literature DB >> 30700445

MicroRNA Dysregulation and Non-Muscle-Invasive Bladder Cancer Prognosis.

Angeline S Andrew1, Margaret R Karagas2, Florian R Schroeck2,3, Carmen J Marsit4, Alan R Schned2, Jason R Pettus2, David A Armstrong2, John D Seigne2.   

Abstract

BACKGROUND: The high rate of non-muscle-invasive bladder cancer recurrence is a major challenge in patient management. miRNAs functionally regulate tumor cell proliferation and invasion, and have strong potential as biomarkers because they are robust to degradation. The objective of this project was to identify reproducible prognostic miRNAs in resected non-muscle-invasive bladder tumor tissue that are predictive of the recurrent tumor phenotype.
METHODS: We utilized patients diagnosed with primary non-muscle-invasive bladder cancer in three independent cohorts for a biomarker discovery/validation approach. Baseline tumor tissue from patients with the clinically challenging, non-muscle-invasive primary low stage (Ta), high grade, and T1 tumors (tumors extending into the lamina propria) comprised the discovery cohort (n = 38). We isolated the tumor tissue RNA and assessed a panel of approximately 800 miRNAs.
RESULTS: miR-26b-5p was the top-ranking prognostic tumor tissue miRNA, with a time-to-recurrence HR 0.043 for levels above versus below median, (P adj = 0.0003). miR-26b-5p was related to a dose-response reduction in tumor recurrence, and levels above the median were also associated with reduced time-to-progression (P adj = 0.02). We used two independent longitudinal cohorts that included both low-grade and high-grade Ta and T1 tumors for validation and found a consistent relationship between miR-26b-5p and recurrence and progression.
CONCLUSIONS: Our results suggest that miR-26b-5p levels may be prognostic for non-muscle-invasive bladder cancer recurrence, and can feasibly be assessed in baseline tumor tissue from a wide variety of clinical settings. IMPACT: Early identification of those non-muscle-invasive bladder tumor patients with refractory phenotypes would enable individualized treatment and surveillance. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30700445      PMCID: PMC6473178          DOI: 10.1158/1055-9965.EPI-18-0884

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  19 in total

1.  Identifying risk factors in patients with non-muscle-invasive bladder cancer: clinical implications.

Authors:  Bernd J Schmitz-Dräger
Journal:  Eur Urol       Date:  2011-08-05       Impact factor: 20.096

2.  Over-expression and amplification of the c-myc gene in human urothelial carcinoma.

Authors:  F Christoph; B Schmidt; B J Schmitz-Dräger; W A Schulz
Journal:  Int J Cancer       Date:  1999-04-20       Impact factor: 7.396

Review 3.  Epidemiology and risk factors of urothelial bladder cancer.

Authors:  Maximilian Burger; James W F Catto; Guido Dalbagni; H Barton Grossman; Harry Herr; Pierre Karakiewicz; Wassim Kassouf; Lambertus A Kiemeney; Carlo La Vecchia; Shahrokh Shariat; Yair Lotan
Journal:  Eur Urol       Date:  2012-07-25       Impact factor: 20.096

Review 4.  Local recurrence after radical cystectomy for invasive bladder cancer: an analysis of predictive factors.

Authors:  Ichiya Honma; Naoya Masumori; Eiji Sato; Akio Takayanagi; Atsushi Takahashi; Naoki Itoh; Mitsuharu Tamagawa; Masa-aki Sato; Taiji Tsukamoto
Journal:  Urology       Date:  2004-10       Impact factor: 2.649

5.  Micro-RNA profiling in kidney and bladder cancers.

Authors:  Fedra Gottardo; Chang Gong Liu; Manuela Ferracin; George A Calin; Matteo Fassan; Pierfrancesco Bassi; Cinzia Sevignani; Dolores Byrne; Massimo Negrini; Francesco Pagano; Leonard G Gomella; Carlo M Croce; Raffaele Baffa
Journal:  Urol Oncol       Date:  2007 Sep-Oct       Impact factor: 3.498

6.  Identification of methylated genes associated with aggressive bladder cancer.

Authors:  Carmen J Marsit; E Andres Houseman; Brock C Christensen; Luc Gagne; Margaret R Wrensch; Heather H Nelson; Joseph Wiemels; Shichun Zheng; John K Wiencke; Angeline S Andrew; Alan R Schned; Margaret R Karagas; Karl T Kelsey
Journal:  PLoS One       Date:  2010-08-23       Impact factor: 3.240

Review 7.  The causal role of cigarette smoking in bladder cancer initiation and progression, and the role of urologists in smoking cessation.

Authors:  Seth A Strope; James E Montie
Journal:  J Urol       Date:  2008-05-15       Impact factor: 7.450

8.  MicroRNA-26a/b and their host genes cooperate to inhibit the G1/S transition by activating the pRb protein.

Authors:  Ying Zhu; Yang Lu; Qi Zhang; Jing-Jing Liu; Tuan-Jie Li; Jian-Rong Yang; Chunxian Zeng; Shi-Mei Zhuang
Journal:  Nucleic Acids Res       Date:  2011-12-30       Impact factor: 16.971

9.  Long term follow-up in patients with initially diagnosed low grade Ta non-muscle invasive bladder tumors: tumor recurrence and worsening progression.

Authors:  Hiroaki Kobayashi; Eiji Kikuchi; Shuji Mikami; Takahiro Maeda; Nobuyuki Tanaka; Akira Miyajima; Ken Nakagawa; Mototsugu Oya
Journal:  BMC Urol       Date:  2014-01-08       Impact factor: 2.264

10.  MicroRNA molecular profiling from matched tumor and bio-fluids in bladder cancer.

Authors:  David A Armstrong; Benjamin B Green; John D Seigne; Alan R Schned; Carmen J Marsit
Journal:  Mol Cancer       Date:  2015-11-14       Impact factor: 27.401

View more
  3 in total

Review 1.  Non-coding RNA-associated competitive endogenous RNA regulatory networks: Novel diagnostic and therapeutic opportunities for hepatocellular carcinoma.

Authors:  Sattar Khashkhashi Moghadam; Babak Bakhshinejad; Ali Khalafizadeh; Bashdar Mahmud Hussen; Sadegh Babashah
Journal:  J Cell Mol Med       Date:  2021-12-14       Impact factor: 5.310

2.  mRNA-miRNA bipartite networks reconstruction in different tissues of bladder cancer based on gene co-expression network analysis.

Authors:  Zahra Abedi; Habib MotieGhader; Sahar Sadat Hosseini; Mohammad Ali Sheikh Beig Goharrizi; Ali Masoudi-Nejad
Journal:  Sci Rep       Date:  2022-04-07       Impact factor: 4.379

3.  Lnc-STYK1-2 regulates bladder cancer cell proliferation, migration, and invasion by targeting miR-146b-5p expression and AKT/STAT3/NF-kB signaling.

Authors:  Ranran Dai; Qingping Jiang; You Zhou; Ruifeng Lin; Hai Lin; Yumin Zhang; Jinhu Zhang; Xingcheng Gao
Journal:  Cancer Cell Int       Date:  2021-07-31       Impact factor: 5.722

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.